Cybin Inc. Common Stock Morgan Stanley 24th Annual Global Healthcare Conference

Sure. And thank you, Rebecca. Thank you, everyone, for joining us today. Certainly excited to talk about Helus Pharma. I'm Michael Halstead, the new CEO of Helus. I joined in early August. Helus Pharma is developing treatments for several mental health indications. We're developing novel serotonergic agonists. Our lead program, our first phase III readout, expected in the fourth quarter of this year, is the molecule is deuterated psilocin. It is in development for the treatment of adjunctive major depressive disorder, MDD. Very excited about that program, that indication in particular. Hopefully, we'll get into that as we progress. Mid-stage program we have as well is our HLP004 program. That is deuterated DMT, the molecule, and that is for the treatment of generalized anxiety disorder. A very important indication there with a real unmet need. We, in the beginning of this year, completed a phase II signal finding study.

We've told everyone that we're finalizing the clinical trial design for the next study in that program this quarter, and we'll be rolling details of that out very soon. The earlier stage program in the platform, and I like to emphasize this is a platform, late stage, mid-stage, and early stage, is our HLP005 program, which is a library of compounds, preclinical, but I think have real potential in a number of mental health-related indications. We're going to be expecting to move the lead molecule in that program forward in 2027. A lot going on. Obviously, a big near-term catalyst with the expected phase III data in Q4, but just really excited about the potential that the company has to make a real positive impact in the treatment of mental health.

Sure. I have been in and around industry for about 25 years. Most recently, I was with Intra-Cellular Therapies, a CNS-focused company, had developed antipsychotics for a treatment of adjunctive MDD that was acquired by Johnson & Johnson in 2025. I was in the fortunate position then of having the opportunity to be very thoughtful, selective about what it was I wanted to do next. Saw the opportunity with Helus to make an impact in, again, very important area, mental health, all the real unmet need. The company is doing just some really great work. I did, I would say, a very similar diligence exercise to what investors do when they look at a company.

Yeah. I looked at the potential of these assets, the likelihood of success.

Obviously, you can have the greatest assets, but if you can't get them to the finish line, then you can't do what our real mission, what we really want to do, make that real patient impact, provide that patient benefit. Then looked at the quality of the team that we have at Helus. All of those things checked out for me, and especially as I look at the Phase III program in adjunctive MDD, and really the platform that the company has- Sure the strong IP underneath to support long-term development, long-term commercialization.

I just think that real potential with the company, and so I decided this was a place to devote my time, my energy.

Three words and they're all the same. Execution, execution. Wow. Obviously, we need to read our data out in Q4 with our late-stage phase III program in adjunctive MDD.

Continuing with that focus on execution, Yeah both from the clinical development perspective, not only with our 003 program, but the other programs I referenced in the platform.

Also in parallel with that, all of the infrastructure building at an appropriate scalable pace, Yeah so that we are prepared as we hopefully achieve these various clinical milestones to then support ultimately successful commercial launch.

Well, actually adjunctive MDD is the broadest indication.